1. Home
  2. LEXX vs XCUR Comparison

LEXX vs XCUR Comparison

Compare LEXX & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.91

Market Cap

22.7M

Sector

Health Care

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$5.96

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEXX
XCUR
Founded
2004
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
26.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LEXX
XCUR
Price
$0.91
$5.96
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
167.8K
1.8M
Earning Date
01-09-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$705,923.00
N/A
Revenue This Year
$13.35
N/A
Revenue Next Year
$78.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
52.05
N/A
52 Week Low
$0.77
$3.10
52 Week High
$2.43
$22.99

Technical Indicators

Market Signals
Indicator
LEXX
XCUR
Relative Strength Index (RSI) 39.27 55.65
Support Level $1.05 $5.15
Resistance Level $1.44 $6.89
Average True Range (ATR) 0.10 1.04
MACD -0.00 0.13
Stochastic Oscillator 11.10 39.72

Price Performance

Historical Comparison
LEXX
XCUR

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About XCUR Exicure Inc.

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Share on Social Networks: